Study of ultro-low dose Decitabine in patients with intermediate-1 risk myelodysplastic syndromes
WANG Hui-han
YAO Kun
WU Bin
MIAO Miao
LI Yang
LIAO Ai-jun
YANG Wei
Abstract：Objective To assess the efficacy and tolerability of ultro-low dose of decitabine in patients with intermediate-1 risk myelodysplastic syndrome (MDS).Method Ten Patients received decitabine,10mg/d,d1～3,d8,di5,d22,every 32 days.Evaluate the effect and adverse event.Results 6/10(60％) patients had gene mutation associated with MDS.After one circle treatment,the OIR was 40％,PR rate was 10％,HI was 30％,SD was 60％.After three circles treatment,the OIR was 67％,CR rate was 33.3％,HI was 33.3％,SD was 33.3％.40％ patients showed bone marrow depression,neutropenia 10％,anemia 10％,thrombocytopenia 10％,≥3grade thrombocytopenia 20％.Conclusion Ultra low dose ofdecitabine was efficient and safe to treat intermediate-1 risk MDS patients.
Keywords：ultro-low dosedecitabineintermediate-1 riskmyelodysplastic syndrome
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 741-744 )